From: Challenges of applying multicellular tumor spheroids in preclinical phase
Tumor type | Cell line | MCTs morphology | Culture conditions (media, peroid, technology) | References |
---|---|---|---|---|
Breast cancer | MCF-7 | CS | RPMI + 10% FCS + L-Glutamine, 24 h, low adhesion plate | [22] |
BT-474 | CS | Sodium pyruvate + HEPES, 24 h, low adhesion plate | ||
T-47D | CS | RPMI + 10% FCS + L-Glutamine, 24 h, low adhesion plate | ||
MDA-MB-361 | CS | RPMI + 10% FCS + L-Glutamine, 24 h, low adhesion plate | ||
MDA-MB-435S | TA | RPMI + 10% FCS + L-Glutamine, 24 h, low adhesion plate | ||
MDA-MB-231 | LA | RPMI + 10% FCS + L-Glutamine, 24 h, low adhesion plate | ||
MDA-MB-468 | LA | RPMI + 10% FCS + L-Glutamine, 24 h, low adhesion plate | ||
SK-BR-3 | LA | McCoy's 5A, 24Â h, low adhesion plate | ||
MCF-7 | CS | RPMI + 25% methocel, 3 days, hanging drop | [4] | |
MDA-MB-231 | TA | RPMI + 25% methocel, 3 days, hanging drop | ||
SK-BR-3 | LA | RPMI + 25% methocel, 3 days, hanging drop | ||
Colon cancer | HCT116 | CS | High glucose, 4Â days culture low adhesion plate | [39] |
DLD-1 | TA | DMEM, 4Â days culture low adhesion plate | ||
SW620 | LA | RPMI, 4Â days, low adhesion plate | ||
Gastric cancer | RF-1 | CS | RPMI, 2Â days, liquid overlay technique | [38] |
RF-48 | CS | RPMI, 2Â days, liquid overlay technique | ||
Hs-746Â T | CS | RPMI, 2Â days, liquid overlay technique | ||
MKN-28 | TA | RPMI, 2Â days, liquid overlay technique | ||
MKN-74 | TA | RPMI, 2Â days, liquid overlay technique | ||
N87 | TA | RPMI, 2Â days, liquid overlay technique | ||
SNU-5 | LA | RPMI, 2Â days, liquid overlay technique | ||
SNU-16 | LA | RPMI, 2Â days, liquid overlay technique | ||
Head and neck cancer | FaDu | CS | RPMI + 10% FCS, 72 h, low adhesion plate | [40] |
HLaC78 | CS | RPMI, 2Â days, liquid overlay technique | ||
HSmC78 | CS | RPMI, 2Â days, liquid overlay technique | ||
Cal27 | CS | RPMI, 2Â days, liquid overlay technique | ||
PE/CA-PJ41 | CS | RPMI, 2Â days, liquid overlay technique | ||
HNO210 | CS | DMEM, 72Â h, low adhesion plate | ||
SCC4 | CS | DMEM/F12, 72Â h, low adhesion plate | ||
FaDu | TA | RPMI, 2Â days, liquid overlay technique | ||
Hep2 | TA | MEM, 72Â h, low adhesion plate | ||
HPaC79 | LA | RPMI, 2Â days, liquid overlay technique | ||
HLaC79 | LA | RPMI, 2Â days, liquid overlay technique | ||
HLaC79-tAX | LA | RPMI, 2Â days, liquid overlay technique | ||
Glioblastoma | U-87 MG | CS | DMEM, 24–48 h, low adhesion plate | [41] |
A172 | CS | DMEM, 24–48 h, low adhesion plate | ||
SF126 | CS | DMEM, 24–48 h, low adhesion plate | ||
LN-229 | CS | DMEM, 24–48 h, low adhesion plate | ||
Neuroblastoma | SH-SY5Y | CS | RPMI, 24–48 h, low adhesion plate | [41] |
KELLY | CS | RPMI, 24–48 h, low adhesion plate | ||
SHEP | TA | RPMI, 24–48 h, low adhesion plate | ||
IMR-32 | TA | DMEM, 24–48 h, low adhesion plate | ||
Pancreatic | PANC-1 | CS | DMEM, 24–48 h, low adhesion plate | [41] |
MIA PaCa-2 | LA | DMEM, 24–48 h, low adhesion plate |